Merck fights latest set of Fosamax fracture claims; HealthCanada pulls mispackaged Apotex contraceptives;

 @FiercePharma: Merck's new Fosamax trial starts today. Was woman's atypical femur fracture caused by drug, or disease? More | Follow @FiercePharma

 @EricPFierce: India delays to 2014 its deadline for drugmakers to put bar codes on primary packaging to fight fakes. More | Follow @EricPFierce

> Merck's second trial over Fosamax links to atypical femur fractures opened today in New Jersey; the first ended in a mistrial. Report

> HealthCanada recalled Apotex's Alysena birth control pill after it found a package that contained twice as many placebo pills as it should have. Report

> The U.K.'s pharma trade group says drug companies paid about £40 million per year to British doctors in service fees, flights, hotel and other travel expenses. Report

> Novartis ($NVS) shares rose after Bank of America hiked its rating to Neutral and raised its price target to $74.71. Report

> A Chinese flu drug maker, Baoshantang Pharmaceutical lost its license after toxins were found in herbal ingredients; the company processed the herbs for China-based pharma major Guangzhou Pharmaceutical. Report

Medical Device News

@FierceMedDev: 'Awake Imaging' boosts Dx prospects for fidgety patients. Article | Follow @FierceMedDev

@MarkHFierce: BSD will use Japan's Terumo to reach global markets with its cancer ablation device. More | Follow @MarkHFierce

 @DamianFierce: Quintiles' founder and early investors will make off with $25M once the CRO goes public. Story | Follow @DamianFierce

> FDA: Woman with HeartWare HVAD dies after device loses power. Article

> Penn Medicine rolls out personalized diagnostics. Item

> 'Awake Imaging' boosts Dx prospects for fidgety patients. More

> Cancer Genetics bags $6.9M in over-allotted IPO. Story

Biotech News

@FierceBiotech: Pharmacyclics bounces higher as J&J wins third 'breakthrough' cancer drug coup. More | Follow @FierceBiotech

@JohnCFierce: Roche rolls out $392M Isis pact in two-prong attack on Huntington's. Story | Follow @JohnCFierce.

@RyanMFierce: Uh oh. biotech outfit Unigene is slashing ~40% of workers to extend cash runway. Release | Follow @RyanMFierce

> Investigator says 'insane' rules are blocking his study on magic mushrooms. More

> Blue chip venture groups arm gene therapy upstart with $41M launch round. News

> In Sunday surprise, Bristol-Myers' R&D chief replaced by lieutenant. Report

CRO News

> InVentiv sells sample management biz to Knipper. More

> Indian trial reform on the way, but does it make sense? Article

> EU CRO TranScrip launches U.S. operation. Item

> AmerisourceBergen sells contract packaging biz for $308M. More

> Bristol-Myers picks LabCorp for CRO work. Story

Biotech IT News

> Survey: Cloud computing tops pharma's IT plans. More

> Life Tech genome software aids cancer-drug hunters in pharma. Report

> New trial search engine steps into congested market. Story

> Big Data hits Eastern Europe as IBM fires up supercomputer. Item

> Computational scientists clear path to potential Parkinson's drugs. Article

And Finally... Scientific publishing faces big changes as cloud computing and crowd-sourcing come to the fore. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.